Artivion (AORT) Q2 2026 Earnings Call Transcript
Artivion (AORT) reported Q2 2026 revenue of $125.8M, up 9% constant currency, and adjusted EBITDA of $26.4M. The company completed the Endospan acquisition and received late-June FDA PMA approval for AMDS, expecting faster account conversion. Full-year guidance was reiterated at $480M to $496M revenue and $92M to $99M adjusted EBITDA; FCF was negative $12M.
How this was made
The 30-second read
Why it matters
The most tradable elements are the late-June FDA PMA approval for AMDS (expected to accelerate US account conversion), the completed Endospan acquisition (adding NEXUS and pipeline programs), and reiterated FY revenue and adjusted EBITDA ranges alongside margin and free cash flow pressures.
Market read
Investors get a combined package of execution signals (regulatory approval, acquisition close, international growth) and near-term financial headwinds (margin compression, negative free cash flow, leverage).
What to watch
Gross margin fell due to geographic mix and Austin ramp costs, and non-GAAP G&A rose from stock-based compensation deleverage, both of which may matter more than top-line growth for near-term multiples.
Background
This is a transcript-style summary of Artivion’s Q2 2026 earnings call, covering financial results, guidance, FDA/regulatory updates, and the Endospan acquisition.
Ticker impact
Artivion reported Q2 2026 results and reiterated FY revenue guidance, while disclosing FDA PMA approval for AMDS and completion of the Endospan acquisition.
Likely choppy trading around guidance and margin commentary, with upside bias if investors believe AMDS conversion and NEXUS launch timing support FY growth.
The article provides concrete operating datapoints (Q2 revenue, EBITDA margin, cash/debt, leverage) plus new regulatory and M&A milestones (AMDS PMA approval, Endospan close) that can re-rate near-term execution risk, but it does not introduce a new FY guidance number beyond reiteration.
Market effects
Device makers with cardiovascular portfolios may see read-across interest in how quickly PMA approvals translate into account conversion and revenue ramp.
International growth re-accelerated (EMEA, Asia Pacific, Latin America), but Middle East instability was flagged as a 2H revenue risk.
FDA device approval and acquisition integration can influence investor sentiment toward the broader aortic repair and structural heart device space.
Counterpoint
Despite PMA approval, preservation services growth is constrained by supply availability and free cash flow remains negative, which could limit near-term valuation support.
Key entities
- companyArtivion, Inc.
Reported Q2 2026 revenue growth, reiterated FY guidance, received FDA PMA approval for AMDS, and completed the Endospan acquisition.
- acquired_businessEndospan
Acquisition completed in Q2, adding the NEXUS Aortic Arch Stent Graft System and additional PMA programs.
- regulatorFDA
Approved AMDS PMA in late June, removing IRB oversight requirement for institutional review.
- productAMDS
Ascyrus Medical Dissection Stent, whose PMA approval is expected to accelerate US account conversion.
- productNEXUS
Branched stent graft system with full commercial launch scheduled for Jan 1, 2027.
